drugset
Drugs / 177Lu-BetaBart
last change Feb 2026 re-read 3 minutes ago

177Lu-BetaBart

Monoclonal antibody

Developed for
castration-resistant prostate carcinoma · cervical cancer · colorectal cancer · endometrial cancer · esophageal squamous cell carcinoma · head and neck squamous cell carcinoma · non-small cell lung carcinoma · ovarian carcinoma
+2 more · small cell lung carcinoma · triple-negative breast carcinoma
Investigated by
Medpace, Inc. · Radiopharm Theranostics, Ltd

Trials 1

today NCT07189871 · Ph 1/2
20272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07189871 Feb 2026 → Dec 2027 expected castration-resistant prostate carcinoma, cervical cancer, colorectal cancer, endometrial cancer +6 Radiopharm Theranostics, Ltd Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 177Lu-BetaBart ClinicalTrials.gov intervention name — accepted as the source's own label NCT07189871 ↗
Modality Monoclonal antibody “177Lu-Labeled Anti-B7-H3 Monoclonal Antibody” NCT07189871 ↗
Route Intravenous “BetaBart administered by intravenous (IV) infusion” NCT07189871 ↗